Business · 13/10/1998Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for Corlopam Patent Extension
Summary
The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for Corlopam, a human drug product, in accordance with patent extension regulations, following a submission to the Commissioner of Patents and Trademarks.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →